YM BioSciences (Formerly York Medical, Inc.)
5045 Orbitor Drive
Building 11, Suite 400
Mississauga
Ontario
L4W4Y4
Canada
Tel: 905-629-9761
Fax: 905-629-4959
Website: http://www.ymbiosciences.com/
Email: ir@ymbiosciences.com
169 articles about YM BioSciences (Formerly York Medical, Inc.)
-
Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
-
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Adds Former YM BioSciences CEO Nick Glover to Board of Directors
6/11/2013
-
Gilead Sciences, Inc. Completes Acquisition of YM BioSciences
2/11/2013
-
YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2013
2/7/2013
-
YM BioSciences Announces Receipt of Final Court Order Approving the Plan of Arrangement With Gilead Sciences, Inc.
2/5/2013
-
YM BioSciences Shareholders Approve Plan of Arrangement With Gilead Sciences, Inc.
2/1/2013
-
YM BioSciences Plan of Arrangement With Gilead Sciences, Inc. Endorsed by Leading Independent Proxy Advisors ISS and Glass Lewis
1/18/2013
-
YM BioSciences Announces Record Date for Previously Announced Plan of Arrangement
12/21/2012
-
Gilead Sciences, Inc. Bags Blood Disorder Drug With $510 Million YM BioSciences Buy
12/13/2012
-
YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 in Myelofibrosis at American Society of Hematology 2012
12/10/2012
-
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
12/4/2012
-
YM BioSciences Announces Election of Dr. Kapil Dhingra to Its Board of Directors
11/21/2012
-
YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2013
11/9/2012
-
YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses
11/5/2012
-
YM BioSciences Reports CYT387 Phase I/II Results Selected for Oral Presentation at American Society of Hematology 2012 Conference
10/11/2012
-
YM BioSciences Reports Fiscal 2012 Operational and Financial Results
9/24/2012
-
YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
5/11/2012
-
YM BioSciences Raises US$80.5 Million from Public Offering
2/29/2012
-
YM BioSciences Prices $70 Million Public Offering of Common Shares
2/27/2012
-
YM BioSciences Announces Proposed Public Offering of Common Shares
2/24/2012